Exosens (EXSNY)
| Market Cap | 3.27B +46.9% |
| Revenue (ttm) | 573.26M +25.5% |
| Net Income | 34.44M -30.2% |
| EPS | 0.68 -32.1% |
| Shares Out | n/a |
| PE Ratio | 94.83 |
| Forward PE | 25.85 |
| Dividend | 0.05 (0.26%) |
| Ex-Dividend Date | May 28, 2026 |
| Volume | n/a |
| Open | 18.50 |
| Previous Close | 18.50 |
| Day's Range | 18.50 - 18.50 |
| 52-Week Range | 16.15 - 19.30 |
| Beta | 0.85 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Exosens
Exosens, together with its subsidiaries, develops, manufactures, and sells electro-optical technologies in France, Europe, North America, Asia, and internationally. It operates in two segments, Amplification and Detection and Imaging. The company offers image intensifier tubes; cameras, sensors, modules and cores, and imaging systems and solutions, including UV missile warning solution, atmospheric sounder, and spectroradiometer; and detection and imaging products for ions and electrons, photons, and neutrons, as well as micro pore optics and c... [Read more]
Financial Performance
In 2025, Exosens's revenue was 468.19 million, an increase of 22.10% compared to the previous year's 383.44 million. Earnings were 42.72 million, an increase of 67.31%.
Financial numbers in EUR Financial StatementsNews
Exosens's Photonis Defense Secures Contract From US Army
(RTTNews) - Exosens (EXENS.PA), a manufacturer of electro-optical technologies, Tuesday announced that its US subsidiary Photonis Defense has secured a first delivery order for 1,600 complete systems ...
Exosens price target raised to EUR 73 from EUR 71 at JPMorgan
JPMorgan raised the firm’s price target on Exosens (EXOSF) to EUR 73 from EUR 71 and keeps an Overweight rating on the shares.
Exosens Earnings Call Transcript: Q2 2026
Revenue grew 15.3% year-over-year to EUR 253.1 million, with strong gains in both Amplification and Detection & Imaging. Adjusted EBITDA margin reached a record 33%, and guidance for 2026 is now at the upper end of previous ranges, supported by robust demand and ongoing capacity expansion.
Exosens Earnings release: Q2 2026
Exosens released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Exosens Slides: Q2 2026
Exosens has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
Exosens Quarterly report: Q2 2026
Exosens has published its Q2 2026 quarterly earnings report on July 28, 2026.
Exosens Slides: FY 2026
Exosens has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 22, 2026.
Exosens price target raised to EUR 60 from EUR 55 at Deutsche Bank
Deutsche Bank analyst Sriram Krishnan raised the firm’s price target on Exosens (EXOSF) to EUR 60 from EUR 55 and keeps a Hold rating on the shares. Published first on…
Exosens price target raised to EUR 72 from EUR 69 at Berenberg
Berenberg raised the firm’s price target on Exosens (EXOSF) to EUR 72 from EUR 69 and keeps a Buy rating on the shares.
Exosens Earnings release: Q1 2026
Exosens released its Q1 2026 earnings on April 27, 2026, summarizing the period's financial results.
Exosens price target raised to EUR 71 from EUR 60 at JPMorgan
JPMorgan analyst David Perry raised the firm’s price target on Exosens (EXOSF) to EUR 71 from EUR 60 and keeps an Overweight rating on the shares.
Exosens price target raised to EUR 55 from EUR 52 at Deutsche Bank
Deutsche Bank analyst Sriram Krishnan raised the firm’s price target on Exosens (EXOSF) to EUR 55 from EUR 52 and keeps a Hold rating on the shares. Published first on…
Exosens price target raised to EUR 59.30 from EUR 37 at Citi
Citi raised the firm’s price target on Exosens (EXOSF) to EUR 59.30 from EUR 37 and keeps a Neutral rating on the shares.
Exosens price target raised to EUR 69 from EUR 57 at Berenberg
Berenberg analyst Amelie Dueckelmann-Dublany raised the firm’s price target on Exosens (EXOSF) to EUR 69 from EUR 57 and keeps a Buy rating on the shares.
Exosens Earnings Call Transcript: Q4 2025
Delivered record 2025 results with 22% revenue growth, 32.4% EBITDA margin, and strong cash flow. Upgraded 2026 guidance, continued capacity expansion, and strategic M&A support midterm ambition to reach EUR 1 billion revenue.
Exosens Earnings release: Q4 2025
Exosens released its Q4 2025 earnings on February 23, 2026, summarizing the period's financial results.
Exosens Slides: Q4 2025
Exosens has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 23, 2026.
Exosens Annual report: Q4 2025
Exosens has published its Q4 2025 annual report on February 23, 2026.
Exosens upgraded to Hold from Reduce at Kepler Cheuvreux
Kepler Cheuvreux analyst Aymeric Poulain upgraded Exosens (EXOSF) to Hold from Reduce with a EUR 47.20 price target
Exosens price target raised to EUR 60 from EUR 54 at JPMorgan
JPMorgan analyst David Perry raised the firm’s price target on Exosens (EXOSF) to EUR 60 from EUR 54 and keeps an Overweight rating on the shares.